- Home
- Publications
- Publication Search
- Publication Details
Title
Ruxolitinib: A Review in Polycythaemia Vera
Authors
Keywords
Acute Myeloid Leukaemia, Hydroxyurea, Myelofibrosis, Ruxolitinib, Myeloproliferative Neoplasm
Journal
DRUGS
Volume 75, Issue 15, Pages 1773-1781
Publisher
Springer Nature
Online
2015-09-11
DOI
10.1007/s40265-015-0470-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
- (2015) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
- (2015) T. Barbui et al. BLOOD
- Mechanisms of thrombogenesis in polycythemia vera
- (2015) Michael H. Kroll et al. BLOOD REVIEWS
- Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
- (2015) Greg L. Plosker DRUGS
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib for the treatment of patients with polycythemia vera
- (2015) Jean-Jacques Kiladjian et al. Expert Review of Hematology
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation
- (2014) I. Politikos et al. BLOOD
- Therapy for myeloproliferative neoplasms: when, which agent, and how?
- (2014) H. L. Geyer et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- The future of JAK inhibition in myelofibrosis and beyond
- (2014) John O. Mascarenhas et al. BLOOD REVIEWS
- Novel and emerging therapies for the treatment of polycythemia vera
- (2014) Srdan Verstovsek et al. Expert Review of Hematology
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Myeloproliferative neoplasms and thrombosis
- (2013) T. Barbui et al. BLOOD
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
- (2013) Xuejun Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Epidemiology of myeloproliferative neoplasms in the United States
- (2013) Jyotsna Mehta et al. LEUKEMIA & LYMPHOMA
- How I treat polycythemia vera
- (2012) F. Passamonti BLOOD
- Ruxolitinib
- (2012) Lily P.H. Yang et al. DRUGS
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
- (2009) G. Barosi et al. BLOOD
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search